In 2023, Moderna initiated a Phase I/II study to generate safety and immunogenicity data of an investigational pandemic influenza vaccine (mRNA 1018) in healthy adults aged 18 years and older. The study included vaccine candidates against H5 and H7 avian influenza viruses. Based on the positive preliminary data from the Phase I/II study, Moderna is preparing to advance mRNA 1018 into Phase III. The Company looks forward to sharing the Phase I/II results at an upcoming scientific meeting. This $590 million award has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Number: 75A50123D00005.